|Mr. Dennis M. Lanfear||Chairman, Pres & CEO||953.53k||N/A||1955|
|Dr. Jean-Frédéric Viret||Chief Financial Officer||509.36k||52.65k||1966|
|Dr. Peter K. Watler||Chief Technical Officer||399.42k||N/A||1962|
|Dr. V. Bryan Lawlis Jr.||Science Director, Director & Member of Supervisory Board||81.25k||N/A||1952|
|Mr. Vincent R. Anicetti||Chief Operating Officer||N/A||N/A||1955|
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Coherus BioSciences, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 8.